Arcutis posts results for roflumilast psoriasis extension trial, NCT04286607

Arcutis Biotherapeutics had one update this week, with new outcome data posted for a long-running extension study of its topical psoriasis treatment.

• The "DERMIS-OLE" study (NCT04286607) is a Phase 3 open-label extension trial testing ARQ-151 cream 0.3% applied once daily for 24 weeks in subjects with chronic plaque psoriasis, with an actual enrollment of 337 participants¹. The study is listed as completed, with a primary completion and study completion date of January 22, 2024¹, and results were first posted on September 9, 2026. Reported safety data showed treatment-emergent adverse event rates of 26.1% in Cohort 1 Group 1, 33.3% in Cohort 1 Group 2, and 56.7% in Cohort 2 (no prior roflumilast cream)¹, with serious adverse event rates of 1.1%, 0%, and 1.7% respectively across the same groups¹.